Professional Documents
Culture Documents
Reviewers Antibody
Reviewers Antibody
Reviewers Antibody
Antibodies
- are immunoglobulins, which react specifically with the antigen that stimulated their production
Antibodies generated in response to a single complex antigen are heterogeneous because they
are formed by many different clones of cells.
Types of Antibodies:
Polyclonal - antibody capable of reacting with a different antigenic determinant on the complex
antigen; heterogenous
Monoclonal - antibody that arise from a single clone of cells, such as a plasma cell tumor
(myeloma); homogenous
The simplest antibody has a Y shape and consists of 4 polypeptide chains: 2 H chains and two L
chains. The 4 chains are covalently linked by disulfide bonds.
Light chains
can be either:
o κ (kappa)
o λ (lambda)
can occur in all classes of immunoglobulins (IgG, IgM, IgA, IgD, and IgE)
amino terminal portion of each L chain contains part of the antigen-binding site.
L chain is composed of one variable domain (VL) and onconstant domain (CL)
Heavy chains
distinct for each of the five immunoglobulin classes and are designated:
o γ (gamma)
o μ (mu)
o α (alpha)
o δ (delta)
o ε (epsilon)
The amino terminal portion of each H chain participates in the antigen-binding site;
H chains have one variable domain (VH) and three or more constant domains (CH) Each
domain is approximately 110 amino acids in length.
Papain - a proteolytic enzyme that can split IgG into two fragments
Fab portion - fragment associated with antigen-binding activity when the peptide bonds in the
hinge region are broken.
Hypervariable - are subregions consisting of extremely variable amino acid sequences form the
antigen-binding site
Complementarity-determining region (CDR) - area where the the hypervariable regions form the
area of the Ig molecule complementary in structure to the antigenic determinant
Hybrid Virus - two viruses infecting a single host cell can swap genetic material, or reassort,
creating hybrid strains with characteristics of each parent virus
Cell Line Production - development requires the discovery of single cell-derived clones that
produce high and consistent levels of the target therapeutic protein. The first step in the
process is the isolation of single, viable cells. Limiting dilution is a technique that relies on
statistical probability but is time consuming.